Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Overall Study	STARTED	EGCG as Putative Neuroprotective Agent	47
Overall Study	STARTED	Placebo	45
Overall Study	Completion of Study Assessment	EGCG as Putative Neuroprotective Agent	31
Overall Study	Completion of Study Assessment	Placebo	33
Overall Study	Completion Without Protocol Violation	EGCG as Putative Neuroprotective Agent	30
Overall Study	Completion Without Protocol Violation	Placebo	33
Overall Study	Participation in MRI Substudy	EGCG as Putative Neuroprotective Agent	17
Overall Study	Participation in MRI Substudy	Placebo	15
Overall Study	Completion of MRI Substudy	EGCG as Putative Neuroprotective Agent	11
Overall Study	Completion of MRI Substudy	Placebo	8
Overall Study	COMPLETED	EGCG as Putative Neuroprotective Agent	32
Overall Study	COMPLETED	Placebo	35
Overall Study	NOT COMPLETED	EGCG as Putative Neuroprotective Agent	15
Overall Study	NOT COMPLETED	Placebo	10

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02008721/flow